On March 26, the 2026 Intelligent Health Technology Conference—centered on “Interdisciplinary Innovation at the Intersection of Medicine and Engineering”—concluded successfully in the World Expo Puxi Science and Innovation Zone in Shanghai’s Huangpu District. Organized jointly by the Shanghai Association for Artificial Intelligence Technology and the Huangpu Central Science & Innovation Zone Construction Working Group Office, with technical guidance from the United Nations Industrial Development Organization (UNIDO) Investment and Technology Promotion Office (ITPO China–Shanghai), the event brought together policymakers, clinicians, academic researchers, and industry leaders to chart a course for collaborative innovation in the era of Intelligent Health 3.0.
At the conference, Lou Wei, President of the Shanghai Association for Artificial Intelligence Technology, underscored that interdisciplinary medical-engineering innovation must move beyond the lab and into real-world clinical practice and everyday life—closing the critical loop from R&D to clinical validation to sustainable commercialization. Chen Yongliang, Executive Deputy Director of the Huangpu Central Science & Innovation Zone Construction Office, highlighted how Huangpu is leveraging its concentration of tier-one hospitals—including Zhongshan Hospital Fudan University—and state-of-the-art translational research infrastructure to foster deep integration among elite clinical institutions, cutting-edge technologies, and specialized health services.
The event marked several pivotal milestones: UNIDO ITPO China–Shanghai formally designated the World Expo Puxi Zone as a “WiiTs Life Sciences Industry Partner”; the Shanghai Association for Artificial Intelligence Technology officially launched its “Medical-Engineering Interdisciplinary Technology and Industrial Innovation Center” on-site; and the “Life Renewal Harbor”—a dedicated intelligent health technology industrial cluster—was inaugurated. Together, these initiatives signal the establishment of a fully integrated ecosystem supporting end-to-end innovation across research, development, clinical deployment, and market adoption.
During the frontier innovations showcase, Liu Rongyun, Vice President of the Shanghai Association for Artificial Intelligence Technology and Founder & CEO of Shengshengji (SSJ), outlined the paradigm shift defining Intelligent Health 3.0. “The most transformative change in health management over the next decade won’t happen inside hospitals—it will unfold in people’s daily lives,” he stated. “Hospitals determine whether disease can be cured; daily health management determines whether people live well—and live longer.” This evolution reflects a fundamental transition: from reactive, episodic care to proactive, continuous physiological sensing; and from intermittent point-in-time assessments to longitudinal, dynamic insights—a core tenet of Intelligent Health 3.0.
This shift carries urgent clinical relevance—particularly in cardiovascular prevention. In China, an estimated 330 million individuals live with pan-vascular diseases, and cardiovascular conditions claim 4.58 million lives annually. Yet conventional electrocardiographic (ECG) monitoring faces persistent limitations: standard resting ECG captures only 10–30 seconds of data, missing paroxysmal arrhythmias; while traditional Holter monitors provide 24-hour recordings, their cumbersome electrode arrays, water restrictions, and requirement for repeated clinic visits severely compromise patient adherence. Compounding this challenge, fewer than 36,000 certified cardiologists in China specialize in ECG interpretation—far short of the estimated 50 million annual diagnostic needs.
Clinical evidence strongly supports long-term, continuous ambulatory ECG monitoring as a superior alternative. Such monitoring significantly improves detection rates for clinically elusive events—including nocturnal paroxysmal atrial fibrillation and asymptomatic bradycardia. It enables dynamic assessment of myocardial ischemia, identifies silent ischemic episodes, quantifies heart rate variability (HRV) to evaluate autonomic nervous system function, informs pharmacotherapy optimization, and verifies pacemaker performance. For high-risk populations—including those with hypertension, diabetes, obstructive sleep apnea, or psychiatric disorders—long-term ECG surveillance serves as a vital early-warning and integrated disease management tool.
In direct response to these unmet clinical needs, SSJ unveiled its FDA-cleared, Class II medical device—the “AI Heart Explorer.” The wearable system delivers three key advances: first, extended-duration monitoring (24–72 hours) with seamless, non-intrusive wearability that preserves normal activities including bathing and sleep; second, clinical-grade accuracy, achieving a 99.6% sensitivity for arrhythmia detection validated against gold-standard 12-lead ECG; and third, seamless hospital integration—already operational with Zhongshan Hospital Fudan University—enabling users to collect data at home and receive physician-reviewed diagnostic reports directly through the hospital’s secure digital platform.
“Historically, patients traveled to hospitals for testing. Today, high-fidelity diagnostics are migrating into daily life,” said Liu Rongyun. “The AI Heart Explorer brings world-class cardiology evaluation into millions of homes—transforming a single clinic visit into sustained, lifelong cardiac protection.” The device is now commercially available via authorized online channels.
Complementing the AI Heart Explorer, SSJ also demonstrated two additional platforms forming a comprehensive “Sense–Insight–Intervene” framework for Intelligent Health 3.0: “AI Neuro Explorer,” an AI-powered analytical engine integrating neurophysiological modeling and computational neuroscience for cognitive and mental health profiling; and the “Golden Light Ionizer,” a physical intervention device applying plasma-based technology—originally developed in national key laboratories—for non-pharmacologic modulation of physiological homeostasis.
Experts at the conference emphasized that true medical-engineering convergence hinges not on technological novelty alone, but on meaningful dialogue across disciplines—and, crucially, on translating breakthrough science into accessible, usable, and scalable health solutions. With its base in Huangpu, SSJ aims to accelerate the global adoption of intelligent health technologies—advancing a future where health is no longer managed reactively, but actively cultivated, continuously monitored, and personally empowered.